Literature DB >> 15593213

Association of a functional CD19 polymorphism with susceptibility to systemic sclerosis.

Naoyuki Tsuchiya1, Kimiko Kuroki, Manabu Fujimoto, Yoshinori Murakami, Thomas F Tedder, Katsushi Tokunaga, Kazuhiko Takehara, Shinichi Sato.   

Abstract

OBJECTIVE: CD19 is overexpressed in B cells from patients with systemic sclerosis (SSc), and plays a crucial role not only for autoantibody production, but also for skin fibrosis in mouse models. We previously reported the association of a GT repeat polymorphism in the 3'-untranslated region (3'-UTR) of CD19 with human systemic lupus erythematosus. In this study, we examined whether CD19 polymorphisms are associated with genetic susceptibility to SSc.
METHODS: A case-control association study was performed for CD19 polymorphisms, -499G>T in the promoter region and a GT repeat polymorphism in the 3'-UTR, in 134 patients with SSc and 96 healthy individuals recruited at Kanazawa University. CD19 expression levels in the peripheral blood naive and memory B cells from SSc patients were examined by 2-color flow cytometry.
RESULTS: Carrier frequencies of the -499T allele in the promoter (odds ratio [OR] 2.18, 95% confidence interval [95% CI] 1.31-3.86, P = 0.003) and of the (GT)(14) allele in the 3'-UTR (OR 1.86, 95% CI 1.05-3.28, P = 0.03) were significantly increased in SSc patients compared with healthy controls. Association was particularly evident in patients with limited cutaneous SSc with anticentromere antibodies. These alleles were in linkage disequilibrium, but the -499T allele seemed to play a primary role. CD19 expression levels in peripheral blood B cells were significantly elevated in both naive (P = 0.0029) and memory (P = 0.0022) B cells from patients with SSc who had the -499T allele as compared with those without the -499T allele.
CONCLUSION: The CD19 -499G>T polymorphism is associated with higher CD19 expression in B cells, and with susceptibility to SSc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15593213     DOI: 10.1002/art.20674

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  26 in total

Review 1.  T cells and B cells in the pathogenesis of systemic sclerosis: recent insights and therapeutic opportunities.

Authors:  Francesco Del Galdo; Carol M Artlett
Journal:  Curr Rheumatol Rep       Date:  2006-04       Impact factor: 4.592

Review 2.  Recent advances on pathogenesis and therapies in systemic sclerosis.

Authors:  Norihito Yazawa; Manabu Fujimoto; Kunihiko Tamaki
Journal:  Clin Rev Allergy Immunol       Date:  2007-10       Impact factor: 8.667

Review 3.  The role of the acquired immune response in systemic sclerosis.

Authors:  Carlo Chizzolini; Francesco Boin
Journal:  Semin Immunopathol       Date:  2015-07-08       Impact factor: 9.623

4.  CD19 and CD32b differentially regulate human B cell responsiveness.

Authors:  Jodi L Karnell; Nazzareno Dimasi; Fredrick G Karnell; Ryan Fleming; Ellen Kuta; Mildred Wilson; Herren Wu; Changshou Gao; Ronald Herbst; Rachel Ettinger
Journal:  J Immunol       Date:  2014-01-17       Impact factor: 5.422

5.  B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis.

Authors:  Minoru Hasegawa; Yasuhito Hamaguchi; Koichi Yanaba; Jean-David Bouaziz; Junji Uchida; Manabu Fujimoto; Takashi Matsushita; Yukiyo Matsushita; Mayuka Horikawa; Kazuhiro Komura; Kazuhiko Takehara; Shinichi Sato; Thomas F Tedder
Journal:  Am J Pathol       Date:  2006-09       Impact factor: 4.307

6.  Similar CD19 dysregulation in two autoantibody-associated autoimmune diseases suggests a shared mechanism of B-cell tolerance loss.

Authors:  Donna A Culton; Matilda W Nicholas; Donna O Bunch; Quan Li Zhen; Thomas B Kepler; Mary Anne Dooley; Chandra Mohan; Patrick H Nachman; Stephen H Clarke
Journal:  J Clin Immunol       Date:  2006-12-29       Impact factor: 8.317

Review 7.  [Scleroderma associated autoantibodies - clinical and diagnostic relevance].

Authors:  R Mierau; E Genth
Journal:  Z Rheumatol       Date:  2006-07       Impact factor: 1.372

8.  Genetic polymorphisms of CYP2D6 oxidation in patients with systemic sclerosis.

Authors:  Jadwiga Skretkowicz; Malgorzata Baranska; Mariola Rychlik-Sych
Journal:  Eur J Clin Pharmacol       Date:  2009-05-15       Impact factor: 2.953

Review 9.  Pulmonary arterial hypertension in connective tissue diseases.

Authors:  Stephen C Mathai; Paul M Hassoun
Journal:  Heart Fail Clin       Date:  2012-07       Impact factor: 3.179

10.  The role of B cells in systemic sclerosis.

Authors:  Marina D Kraaij; Jacob M van Laar
Journal:  Biologics       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.